Advertisement

Drugs & Therapy Perspectives

, Volume 28, Issue 8, pp 6–10 | Cite as

Ustekinumab: a guide to its use in plaque psoriasis

  • Gillian M. Keating
  • Jamie D. Croxtall
Adis Drug Clinical Q&A
  • 75 Downloads

Abstract

Subcutaneous ustekinumab (Stelara®) improves symptoms in patients with moderate to severe plaque psoriasis and is more effective than etanercept. Subcutaneous ustekinumab is generally well tolerated, with infections being the most commonly reported adverse event.

Keywords

Psoriasis Etanercept Plaque Psoriasis Ustekinumab Mount Sinai School 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Hsu S, Papp KA, Lebwohl MG, et al. Consensus guidelines for the management of plaque psoriasis. Arch Dermatol 2012 Jan; 148 (1): 95–102PubMedCrossRefGoogle Scholar
  2. 2.
    Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 May; 58 (5): 826–50PubMedCrossRefGoogle Scholar
  3. 3.
    Croxtall JD. Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011; 71 (13): 1733–53PubMedCrossRefGoogle Scholar
  4. 4.
    Stelara (ustekinumab): summary of product characteristics. London: European Medicines Agency, 2011 Sep 20Google Scholar
  5. 5.
    Stelara® (ustekinumab): US prescribing information. Centocor Biotech Inc., 2011 AugGoogle Scholar
  6. 6.
    Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 May 17; 371 (9625): 1665–74PubMedCrossRefGoogle Scholar
  7. 7.
    Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008 May 17; 371 (9625): 1675–84PubMedCrossRefGoogle Scholar
  8. 8.
    Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010 Jan 14; 362 (2): 118–28PubMedCrossRefGoogle Scholar
  9. 9.
    Lebwohl M, Yeilding N, Szapary P, et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for dosing recommendations. J Am Acad Dermatol 2010 Oct; 63 (4): 571–9PubMedCrossRefGoogle Scholar
  10. 10.
    Ghislain P, Poulin Y, Wasel N, et al. Maintenance of long-term efficacy of ustekinumab through year 3 for patients with moderate-to-severe psoriasis [abstract no. P589]. 19th Congress of the European Academy of Dermatology and Venerology; 2010 Oct 6–10; GothenburgGoogle Scholar
  11. 11.
    Lebwohl M, Papp K, Han C, et al. Ustekinumab improves health-related quality of life in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial. Br J Dermatol 2010 Jan; 162 (1): 137–46PubMedCrossRefGoogle Scholar
  12. 12.
    Langley RG, Feldman SR, Han C, et al. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol 2010 Sep; 63 (3): 457–65PubMedCrossRefGoogle Scholar
  13. 13.
    Igarashi A, Kato T, Kato M, et al. Efficacy and safety of ustekinumab in Japanese patients with moderate-to-severe plaque-type psoriasis: long-term results from a phase 2/3 clinical trial. J Dermatol 2012 Mar; 39 (3): 242–52PubMedCrossRefGoogle Scholar
  14. 14.
    Tsai TF, Ho JC, Song M, et al. Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: a phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL). J Dermatol Sci 2011 Sep; 63 (3): 154–63PubMedCrossRefGoogle Scholar
  15. 15.
    Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate-to-severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011 Apr; 164 (4): 862–72PubMedCrossRefGoogle Scholar
  16. 16.
    Lebwohl M, Leonardi C, Griffiths CE, et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (part I of II): results from analyses of general safety parameters from pooled phase 2 and 3 clinical trials. J Am Acad Dermatol 2012 May; 66 (5): 731–41PubMedCrossRefGoogle Scholar
  17. 17.
    Gordon KB, Papp KA, Langley RG, et al. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (part II ofII): results from analyses ofinfections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol 2012 May; 66 (5): 742–51PubMedCrossRefGoogle Scholar
  18. 18.
    Krueger G, Langley R, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007; 356 (6): 580–92PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2012

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations